Astria Therapeutics (ATXS) Common Equity: 2017-2019
Historic Common Equity for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $38.3 million.
- Astria Therapeutics' Common Equity fell 5.54% to $38.3 million in Q3 2019 from the same period last year, while for Sep 2019 it was $38.3 million, marking a year-over-year decrease of 5.54%. This contributed to the annual value of $34.9 million for FY2018, which is 196.32% up from last year.
- Per Astria Therapeutics' latest filing, its Common Equity stood at $38.3 million for Q3 2019, which was down 11.73% from $43.4 million recorded in Q2 2019.
- Astria Therapeutics' Common Equity's 5-year high stood at $49.9 million during Q1 2019, with a 5-year trough of $11.8 million in Q4 2017.
- Moreover, its 3-year median value for Common Equity was $34.9 million (2018), whereas its average is $30.8 million.
- As far as peak fluctuations go, Astria Therapeutics' Common Equity slumped by 46.02% in 2018, and later spiked by 285.65% in 2019.
- Over the past 3 years, Astria Therapeutics' Common Equity (Quarterly) stood at $11.8 million in 2017, then soared by 196.32% to $34.9 million in 2018, then decreased by 5.54% to $38.3 million in 2019.
- Its last three reported values are $38.3 million in Q3 2019, $43.4 million for Q2 2019, and $49.9 million during Q1 2019.